Dr Xavier Anguela
Xavier Anguela joined Spark Therapeutics as the Discovery Research leader in 2014. Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing one-time, life-altering treatments for debilitating genetic diseases. One of his main roles at Spark is to lead the preclinical programs designed to address a broad spectrum of genetic diseases.
Prior to his role at Spark, Dr. Anguela was a Howard Hughes Research Associate at the Center for Cellular and Molecular Therapeutics at The Children’s Hospital of Philadelphia in the laboratory of Dr. Katherine High. During his time at CCMT, he developed in vivo genome editing approaches for hemophilia and other genetic diseases, helping lay the foundation for therapeutic use of nuclease technologies in predominantly non-cycling tissues such as the liver.
Dr. Anguela has a PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona. During his doctoral research, he developed a non-viral gene therapy approach to prevent the development of type 1 diabetes in a mouse model of the disease.
18-Jan-2017Case study 1